Cleared Traditional

K892125 - EZ COMPLEMENT C2

K892125 is the FDA 510(k) clearance for EZ COMPLEMENT C2 by Diamedix Corp.. It is a Class 2 Immunology device (product code CZW) cleared through the Traditional 510(k) pathway after a 18-day FDA review.

K892125 · Diamedix Corp. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 1989
Decision
18d
Days
Class 2
Risk

K892125 is an FDA 510(k) clearance for the EZ COMPLEMENT C2. Classified as Complement C3, Antigen, Antiserum, Control (product code CZW), Class II - Special Controls.

Submitted by Diamedix Corp. (Miami, US). The FDA issued a Cleared decision on April 14, 1989 after a review of 18 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5240 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Diamedix Corp. devices

Submission Details

510(k) Number K892125 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 27, 1989
Decision Date April 14, 1989
Days to Decision 18 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
86d faster than avg
Panel avg: 104d · This submission: 18d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code CZW Complement C3, Antigen, Antiserum, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5240
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - CZW Complement C3, Antigen, Antiserum, Control

All 28
Devices cleared under the same product code (CZW) and FDA review panel - the closest regulatory comparables to K892125.
IL TEST COMPLEMENT 3
K920007 · Instrumentation Laboratory CO · Jun 1992
RAICHEM SPIA C3 REAGENT
K911900 · Reagents Applications, Inc. · May 1991
C3C AND C4 RID KITS
K902382 · The Binding Site, Ltd. · Sep 1990
EZ COMPLEMENT C3
K892127 · Diamedix Corp. · Apr 1989
THE TURBOX ANALYSER SYSTEM COMPLEMENT C3 AND C4
K890675 · Unipath , Ltd. · Mar 1989
QM300 C3 ANTIBODY PACK
K871939 · Kallestad Diag, A Div. of Erbamont, Inc. · Jun 1987